TY - STD TI - Guideline for the use of antiretroviral agents in HIV- infected adults and adolescents. 2009, Department of heath and human services and the Henry J. Kaiser family foundation, ID - ref1 ER - TY - JOUR AU - Hammer, S. M. AU - Eron, J. J. AU - Reiss, P. PY - 2008 DA - 2008// TI - Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel JO - JAMA VL - 300 UR - https://doi.org/10.1001/jama.300.5.555 DO - 10.1001/jama.300.5.555 ID - Hammer2008 ER - TY - JOUR AU - Nelson, M. R. AU - Katlama, C. AU - Montaner, J. S. PY - 2007 DA - 2007// TI - The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years JO - AIDS VL - 21 UR - https://doi.org/10.1097/QAD.0b013e3280b07b33 DO - 10.1097/QAD.0b013e3280b07b33 ID - Nelson2007 ER - TY - JOUR AU - Smith, K. Y. AU - Patel, P. AU - Fine, D. PY - 2009 DA - 2009// TI - Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment JO - AIDS VL - 23 UR - https://doi.org/10.1097/QAD.0b013e32832cbcc2 DO - 10.1097/QAD.0b013e32832cbcc2 ID - Smith2009 ER - TY - JOUR AU - Gallant, J. E. AU - Parish, M. A. AU - Keruly, J. C. AU - Moore, R. D. PY - 2005 DA - 2005// TI - Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment JO - Clin Infect Dis VL - 40 UR - https://doi.org/10.1086/428840 DO - 10.1086/428840 ID - Gallant2005 ER - TY - JOUR AU - Gallant, J. E. AU - Staszewski, S. AU - Pozniak, A. L. PY - 2004 DA - 2004// TI - Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial JO - JAMA VL - 292 UR - https://doi.org/10.1001/jama.292.2.191 DO - 10.1001/jama.292.2.191 ID - Gallant2004 ER - TY - JOUR AU - Jones, R. AU - Stebbing, J. AU - Nelson, M. PY - 2004 DA - 2004// TI - Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study JO - J Acquir Immune Defic Syndr VL - 37 UR - https://doi.org/10.1097/01.qai.0000138983.45235.02 DO - 10.1097/01.qai.0000138983.45235.02 ID - Jones2004 ER - TY - JOUR AU - Gallant, J. E. AU - Winston, J. A. AU - DeJesus, E. PY - 2008 DA - 2008// TI - The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients JO - AIDS VL - 22 UR - https://doi.org/10.1097/QAD.0b013e3283112b8e DO - 10.1097/QAD.0b013e3283112b8e ID - Gallant2008 ER - TY - JOUR AU - Gazzard, B. G. AU - Anderson, J. AU - Babiker, A. PY - 2008 DA - 2008// TI - British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 JO - HIV Med VL - 9 UR - https://doi.org/10.1111/j.1468-1293.2008.00636.x DO - 10.1111/j.1468-1293.2008.00636.x ID - Gazzard2008 ER - TY - CHAP PY - 2003 DA - 2003// BT - Treatment Guidelines for a public Health Approach PB - Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) CY - Geneva ID - ref10 ER - TY - JOUR AU - Labarga, P. AU - Medrano, J. AU - Seclen, E. PY - 2010 DA - 2010// TI - Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients JO - AIDS VL - 24 UR - https://doi.org/10.1097/QAD.0b013e3283322895 DO - 10.1097/QAD.0b013e3283322895 ID - Labarga2010 ER - TY - JOUR AU - Weberschock, T. AU - Gholam, P. AU - Hueter, E. AU - Flux, K. AU - Hartmann, M. PY - 2009 DA - 2009// TI - Long-term Efficacy and Safety of Once-daily Nevirapine in Combination with Tenofovir and Emtricitabine in the Treatment of HIV-infected Patients: A 72-week Prospective Multicenter Study (TENOR-Trial) JO - Eur J Med Res VL - 14 UR - https://doi.org/10.1186/2047-783X-14-12-516 DO - 10.1186/2047-783X-14-12-516 ID - Weberschock2009 ER - TY - JOUR AU - Manosuthi, W. AU - Sungkanuparph, S. AU - Tantanathip, P. PY - 2009 DA - 2009// TI - A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study JO - Clin Infect Dis VL - 48 UR - https://doi.org/10.1086/599114 DO - 10.1086/599114 ID - Manosuthi2009 ER - TY - JOUR AU - Levey, A. S. AU - Bosch, J. P. AU - Lewis, J. B. AU - Greene, T. AU - Rogers, N. AU - Roth, D. PY - 1999 DA - 1999// TI - A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group JO - Ann Intern Med VL - 130 UR - https://doi.org/10.7326/0003-4819-130-6-199903160-00002 DO - 10.7326/0003-4819-130-6-199903160-00002 ID - Levey1999 ER - TY - JOUR AU - Kearney, B. P. AU - Flaherty, J. F. AU - Shah, J. PY - 2004 DA - 2004// TI - Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics JO - Clin Pharmacokinet VL - 43 UR - https://doi.org/10.2165/00003088-200443090-00003 DO - 10.2165/00003088-200443090-00003 ID - Kearney2004 ER - TY - JOUR AU - Antoniou, T. AU - Park-Wyllie, L. Y. AU - Tseng, A. L. PY - 2003 DA - 2003// TI - Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection JO - Pharmacotherapy VL - 23 UR - https://doi.org/10.1592/phco.23.1.29.31915 DO - 10.1592/phco.23.1.29.31915 ID - Antoniou2003 ER - TY - JOUR AU - Badiou, S. AU - De Boever, C. M. AU - Terrier, N. AU - Baillat, V. AU - Cristol, J. P. AU - Reynes, J. PY - 2006 DA - 2006// TI - Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? JO - J Infect VL - 52 UR - https://doi.org/10.1016/j.jinf.2005.07.020 DO - 10.1016/j.jinf.2005.07.020 ID - Badiou2006 ER - TY - JOUR AU - Jao, J. AU - Wyatt, C. M. PY - 2010 DA - 2010// TI - Antiretroviral medications: adverse effects on the kidney JO - Adv Chronic Kidney Dis VL - 17 UR - https://doi.org/10.1053/j.ackd.2009.07.009 DO - 10.1053/j.ackd.2009.07.009 ID - Jao2010 ER - TY - JOUR AU - Izzedine, H. AU - Isnard-Bagnis, C. AU - Hulot, J. S. PY - 2004 DA - 2004// TI - Renal safety of tenofovir in HIV treatment-experienced patients JO - AIDS VL - 18 UR - https://doi.org/10.1097/00002030-200404300-00019 DO - 10.1097/00002030-200404300-00019 ID - Izzedine2004 ER - TY - JOUR AU - Day, S. L. AU - Leake Date, H. A. AU - Bannister, A. AU - Hankins, M. AU - Fisher, M. PY - 2005 DA - 2005// TI - Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice JO - J Acquir Immune Defic Syndr VL - 38 ID - Day2005 ER - TY - JOUR AU - Judd, A. AU - Boyd, K. L. AU - Stohr, W. PY - 2010 DA - 2010// TI - Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study JO - AIDS VL - 24 UR - https://doi.org/10.1097/QAD.0b013e3283333680 DO - 10.1097/QAD.0b013e3283333680 ID - Judd2010 ER - TY - JOUR AU - Zimmermann, A. E. AU - Pizzoferrato, T. AU - Bedford, J. AU - Morris, A. AU - Hoffman, R. AU - Braden, G. PY - 2006 DA - 2006// TI - Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions JO - Clin Infect Dis VL - 42 UR - https://doi.org/10.1086/499048 DO - 10.1086/499048 ID - Zimmermann2006 ER - TY - JOUR AU - Irizarry-Alvarado, J. M. AU - Dwyer, J. P. AU - Brumble, L. M. AU - Alvarez, S. AU - Mendez, J. C. PY - 2009 DA - 2009// TI - Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases JO - AIDS Read VL - 19 ID - Irizarry-Alvarado2009 ER - TY - JOUR AU - Erickson, D. A. AU - Mather, G. AU - Trager, W. F. AU - Levy, R. H. AU - Keirns, J. J. PY - 1999 DA - 1999// TI - Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450 JO - Drug Metab Dispos VL - 27 ID - Erickson1999 ER - TY - STD TI - FDA Viramune Prescribing Information: 9-06/24/08, Accessed 03/12/09, http://www.fda.gov/cder/foi/label/2008/020636s027,020933s017lbl.pdf UR - http://www.fda.gov/cder/foi/label/2008/020636s027,020933s017lbl.pdf ID - ref25 ER - TY - JOUR AU - Cihlar, T. AU - Ray, A. S. AU - Laflamme, G. PY - 2007 DA - 2007// TI - Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors JO - Antivir Ther VL - 12 ID - Cihlar2007 ER - TY - JOUR AU - Rodriguez-Novoa, S. AU - Labarga, P. AU - Soriano, V. PY - 2009 DA - 2009// TI - Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study JO - Clin Infect Dis VL - 48 UR - https://doi.org/10.1086/598507 DO - 10.1086/598507 ID - Rodriguez-Novoa2009 ER - TY - JOUR AU - Wever, K. AU - van Agtmael, M. A. AU - Carr, A. PY - 2010 DA - 2010// TI - Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men JO - J Acquir Immune Defic Syndr VL - 55 UR - https://doi.org/10.1097/QAI.0b013e3181d05579 DO - 10.1097/QAI.0b013e3181d05579 ID - Wever2010 ER -